Daily Bio News Summary — 2026-10-05: Three deals, a Nobel for optogenetics, and an FDA week split between approvals and a delay

Monday’s file adds eleven news items compiled from public sources, dated 2026-09-30 through 2026-10-05. The batch is deal-heavy at the top and regulatory in the middle: three separate licensing or acquisition moves, a Nobel Prize for a foundational research tool, two FDA-related product items, one FDA review delay, and two clinical-data updates. No new company profiles were needed — every company referenced here already has a profile in the collection. Endpoints News contributed nothing to the final set: as in the last several runs, the entire domain rendered as soft-paywall stubs and was dropped before per-article verification, so the Endpoints-only stories of the day are intentionally absent rather than missed.

Deal flow: three moves in one day

The batch’s center of gravity is transactional. Shionogi is acquiring rare-disease specialist IntraBio for about $2bn (Pharmaphorum, 2026-10-05), a diversification step that takes the Japanese anti-infectives house further into neurology. In the same direction, Genentech has signed a deal worth up to $1.27bn to access a preclinical blood-brain barrier asset from Alector (BioSpace, 2026-10-05) — a partnership that puts a large neurology buyer behind an early-stage platform play. And CSL has agreed to pay up to $1.6bn to co-develop an Alentis Therapeutics autoimmune candidate (BioSpace, 2026-10-05), pairing a commercial-scale partner with a claudin-targeting asset.

Read together, the three deals say more than any one of them: the day’s capital went to neurology and immunology-adjacent assets, and two of the three are structured as risk-shared, milestone-heavy arrangements rather than outright purchases. The frontmatter does not carry the specific milestone triggers or the asset names behind the CSL and Genentech structures, so treat the headline totals as ceilings rather than cash on the table.

Regulatory: approvals, a biosimilar, a delay, and a psychedelic consultation

The regulatory cluster is unusually mixed. On the positive side, Abbott has an FDA approval for new capabilities in its CardioMEMS HF System (PR Newswire, 2026-10-05), an implantable remote-monitoring device for heart-failure patients; and OMLYCLO (omalizumab-igec), described as the first and only FDA-approved interchangeable biosimilar to Xolair, is now commercially available in the US (PR Newswire, 2026-10-05) — the interchangeable designation is the part that matters commercially, since it permits substitution at the pharmacy counter.

The counterweight is a setback: Novo Nordisk’s US review of a hemophilia candidate has been extended after the FDA flagged corrections at a manufacturing site (Fierce Pharma, 2026-10-05). This is a manufacturing-driven delay rather than a clinical or efficacy failure, which is a materially different problem — and a recurring one across the industry’s recent approvals.

Finally, the FDA opened a public-comment process to support research into ibogaine (FDA Newsroom, 2026-10-05), the psychedelic compound being studied for addiction and other psychiatric uses. A request for input is not an approval or a policy change; it is the agency signalling that it wants a documented evidence base before it moves.

Clinical data: Biogen’s lupus bet and Lilly’s incretin combination

Two data updates anchor the science side. Biogen reported new durability data for its lupus treatment in cutaneous disease (BioSpace, 2026-10-05), a signal that supports its sizable investment in the program — durability, not just initial response, is the variable that decides whether an immunology asset becomes a franchise. And Lilly reported that its investigational EloraTZP combination of eloralintide and tirzepatide delivered greater weight loss and A1c reduction than tirzepatide 15 mg alone in adults with obesity and type 2 diabetes (PR Newswire, 2026-09-30). The comparison is against the company’s own highest-dose incumbent, which is the harder bar to clear and the reason the item reads as a pipeline-defence story as much as a data story.

Recognition and commercialization

Two items sit outside the clinical and financial buckets. The 2026 Nobel Prize in Physiology or Medicine went to the trio behind optogenetics (Pharmaphorum, 2026-10-05), the light-based method for switching neurons on and off that became a standard tool in neuroscience — a reminder that the research that reshapes drug discovery is often a measurement or control technique, not a molecule. And BridgeBio is mounting a YouTube- and community-voice campaign to raise awareness of ATTR-CM (Fierce Pharma, 2026-10-05), the rare heart condition its drug Attruby treats; disease-awareness marketing is how a small company tries to widen a narrow diagnosed population.

What this batch is NOT telling us

• No Endpoints News items at all, by the source’s known soft-paywall behaviour — the domain was dropped wholesale before per-article verification for the fifth consecutive run.
• No BioPharma Dive items (its homepage date format has been unparseable since early August) and no Reuters Biopharma items (the homepage rendered as a title-only shell again).
• No novel-molecule FDA approvals — the day’s approvals are a device capability expansion and a biosimilar, not a new chemical entity.
• No IPOs or AI-bio news in this batch; the day’s capital was private and partnered, not public-market-facing.

Reading order

For a reader with limited time: (1) the Lilly EloraTZP readout, because it is the day’s only head-to-head clinical claim; (2) the Genentech–Alector and CSL–Alentis deals as a pair, since they show where large-company capital is going; (3) the Novo hemophilia delay, which is the batch’s clearest reminder that manufacturing, not just science, gates approvals; (4) the Biogen lupus durability data.

How to read the underlying articles

Each item below corresponds to a markdown file in src/content/news/, which carries the original sourceUrl, sourceName and pubDate. Facts in this summary are limited to what those frontmatter fields state; anything beyond them is flagged as an open question rather than asserted.

Items in this batch

1. Nobel Prize in Medicine awarded to optogenetics trio — Pharmaphorum, 2026-10-05
2. Shionogi’s diversification continues with $2bn IntraBio buy — Pharmaphorum, 2026-10-05
3. Abbott receives FDA approval for new CardioMEMS HF System capabilities — PR Newswire FDA, 2026-10-05
4. OMLYCLO (omalizumab-igec), first FDA-approved interchangeable biosimilar to Xolair, now commercially available in the US — PR Newswire FDA, 2026-10-05
5. Novo cites production site corrections amid hemophilia FDA delay — Fierce Pharma, 2026-10-05
6. BridgeBio gears up for YouTube ATTR-CM awareness push — Fierce Pharma, 2026-10-05
7. FDA Seeks Public Input to Support Ibogaine Research — FDA Newsroom, 2026-10-05
8. Genentech pens $1.27B deal to access Alector’s preclinical blood-brain barrier asset — BioSpace, 2026-10-05
9. CSL strikes up to $1.6B deal with Alentis for autoimmune drug with broad potential — BioSpace, 2026-10-05
10. Biogen’s big lupus bet gets boost from new durability data for skin disease — BioSpace, 2026-10-05
11. Lilly’s EloraTZP combination delivered greater weight loss and A1c reduction vs tirzepatide 15 mg — PR Newswire FDA, 2026-09-30